Th1 vaccination priming for active immunotherapy

Inventors

Har-Noy, Michael

Assignees

Mirror Biologics Inc

Abstract

The present invention includes vaccine compositions and methods for using these vaccine compositions in active immunotherapy. The vaccine compositions include allogeneic activated Th1 memory cells. The compositions can also include one or more disease-related antigens. The methods include administering the vaccine compositions to provide a Th1 footprint in normal individuals or patients susceptible to disease or having minimal residual disease.

Core Innovation

The invention provides therapeutic vaccine compositions and active immunotherapy methods using allogeneic activated Th1 memory cells to create a Th1 footprint in a patient. The method is directed to remission and minimal residual disease, where an anti-alloantigen immunity is developed when the individual is in remission and not exhibiting symptoms from cancer. The priming composition is administered to increase Th1 anti-alloantigen specific titer in circulation.

The priming step includes allogeneic activated Th1 memory cells and cross-linking agents that cross-link CD3 and CD28 surface moieties on the Th1 memory cells at the time of administration. After the anti-alloantigen immunity is developed, one or more cancer-related antigens are administered to the primed individual prior to cancer recurrence. When the individual develops symptoms of the cancer, the method activates the anti-alloantigen immunity by administering an activating composition.

The activating composition comprises allogeneic activated Th1 memory cells and one or more cancer-related antigens. The disclosure also describes preferred generation of Th1 memory cells using CD3/CD28 cross-linking and characterizes Th1 skewing in terms of markers and cytokines. It further describes concepts for booster compositions and timing of boosters relative to prior allogeneic administration.

Claims Coverage

The independent claim covers a three-phase regimen with 3 inventive features: priming to develop anti-alloantigen Th1 immunity in remission, administration of cancer-related antigens before recurrence, and activation of the anti-alloantigen immunity at symptom onset using an activating composition that includes allogeneic activated Th1 memory cells and cancer-related antigens.

The independent claim ties together a priming step that uses CD3/CD28 cross-linked allogeneic activated Th1 memory cells to induce Th1 anti-alloantigen specific titer during remission, a subsequent administration of cancer-related antigens before recurrence, and an activation step at symptom onset using an activating composition that again includes allogeneic activated Th1 memory cells together with cancer-related antigens.

Stated Advantages

Documented Applications